Literature DB >> 17208987

Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance.

Giancarla A Botelho-Santos1, Walkyria O Sampaio, Timothy L Reudelhuber, Michael Bader, Maria J Campagnole-Santos, Robson A Souza dos Santos.   

Abstract

We have described a transgenic rat line that expresses an angiotensin-(1-7)-producing fusion protein, the TGR(A1-7)3292. In these rats, testis acts as an angiotensin-(1-7) biological pump, increasing its plasma concentration 2.5-fold. In this study, we performed hemodynamic measurements in TGR(A1-7)3292 and age-matched Hannover Sprague-Dawley (SD) control rats, using fluorescent microspheres. Urethane-anesthetized transgenic rats had similar levels of baseline blood pressure (99 +/- 3 mmHg) as did SD rats (101 +/- 3 mmHg). However, pronounced differences were observed in other hemodynamic measurements. TGR(A1-7)3292 rats presented a significant increase in stroke volume (0.29 +/- 0.01 vs. 0.25 +/- 0.01 ml in SD), increased cardiac index (24.6 +/- 0.91 vs. 21.9 +/- 0.65 ml.min(-1).kg) and decreased total peripheral resistance (3.9 +/- 0.13 vs. 4.5 +/- 0.13 mmHg.ml(-1).min.100 g). The increase in stroke volume in transgenic rats may be partially explained by the small decrease in heart rate (326 +/- 7.0 vs. 359 +/- 6.0 beats/min in SD). Strikingly, TGR(A1-7)3292 rats presented a substantial decrease in the vascular resistance in lung, spleen, kidney, adrenals, brain, testis and brown fat tissue with no significant differences in the left ventricle, mesentery, skin, gastrocnemius muscle and white fat tissue. These results corroborate and extend previous results observed after acute angiotensin-(1-7) infusion, showing that chronic increase in circulating angiotensin-(1-7) produces sustained and important changes in regional and systemic hemodynamics. Moreover, our data suggest a physiological role for angiotensin-(1-7) in the tonic control of regional blood flow.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17208987     DOI: 10.1152/ajpheart.01245.2006

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  23 in total

Review 1.  The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.

Authors:  Ana Cristina Simões E Silva; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2011-09-23       Impact factor: 3.714

2.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 3.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

4.  Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol.

Authors:  Jasmina Varagic; Sarfaraz Ahmad; K Bridget Brosnihan; Javad Habibi; Roger D Tilmon; James R Sowers; Carlos M Ferrario
Journal:  Am J Nephrol       Date:  2010-11-02       Impact factor: 3.754

5.  Angiotensin-(1-7) recruits muscle microvasculature and enhances insulin's metabolic action via mas receptor.

Authors:  Zhuo Fu; Lina Zhao; Kevin W Aylor; Robert M Carey; Eugene J Barrett; Zhenqi Liu
Journal:  Hypertension       Date:  2014-04-07       Impact factor: 10.190

6.  In vivo expression of angiotensin-(1-7) lowers blood pressure and improves baroreflex function in transgenic (mRen2)27 rats.

Authors:  Maria A Garcia-Espinosa; Hossam A Shaltout; Patricia E Gallagher; Mark C Chappell; Debra I Diz
Journal:  J Cardiovasc Pharmacol       Date:  2012-08       Impact factor: 3.105

Review 7.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

8.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

Review 9.  Nonclassical renin-angiotensin system and renal function.

Authors:  Mark C Chappell
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

10.  Angiotensin-(1-7) mitigated angiotensin II-induced abdominal aortic aneurysms in apolipoprotein E-knockout mice.

Authors:  Fei Xue; Jianmin Yang; Jing Cheng; Wenhai Sui; Cheng Cheng; Hongxuan Li; Meng Zhang; Jie Zhang; Xingli Xu; Jing Ma; Lin Lu; Jinfeng Xu; Meng Zhang; Yun Zhang; Cheng Zhang
Journal:  Br J Pharmacol       Date:  2020-03-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.